Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
Empagliflozin shows a clear clinical advantage by reducing the combined risk of dying from cardiovascular causes or the likelihood of first hospitalization for heart failure compared to placebo plus standard care. However, the lack of direct comparison with dapagliflozin limits the strength of the evidence.
Cost effectiveness
Empagliflozin is suggested to have similar costs to dapagliflozin, which supports its cost-effectiveness under common thresholds, making it a viable option for treatment.
Quality of life
The indirect comparison suggests that empagliflozin has a similar effect on quality of life as dapagliflozin, indicating moderate improvements in HRQoL, although specific validated tools were not mentioned.
Supporting Domains
Safety and Adverse Effects
The document does not highlight significant safety concerns, indicating an acceptable safety profile, although specific adverse effects were not detailed.
Comparator Selection
While empagliflozin was compared to placebo plus standard care, the absence of direct head-to-head trials with dapagliflozin raises concerns about the robustness of the comparator selection.
Patient Population and Subgroups
The trial population appears to be representative of adults with chronic heart failure with preserved or mildly reduced ejection fraction, although subgroup analyses were not explicitly mentioned.
Care Pathway Integration
Empagliflozin can be integrated into existing care pathways with minor adjustments, as it is recommended alongside standard care for chronic heart failure.
Resource Use and Cost Implications
The annual treatment cost of empagliflozin is reasonable and aligns with the expected budget impact, indicating a manageable resource use.
Evidence Quality and Robustness
The evidence is based on clinical trials, although the lack of direct comparisons introduces some methodological concerns.
Uncertainty, Sensitivity, and Broader Impacts
While there are some uncertainties regarding the indirect comparisons, the overall context supports the use of empagliflozin in addressing an unmet need in chronic heart failure.
